NASDAQ:IFRX - InflaRx Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $8.80
  • Forecasted Upside: 252.00 %
  • Number of Analysts: 7
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$2.50
▼ -0.03 (-1.19%)

This chart shows the closing price for IFRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New InflaRx Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IFRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IFRX

Analyst Price Target is $8.80
▲ +252.00% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for InflaRx in the last 3 months. The average price target is $8.80, with a high forecast of $16.00 and a low forecast of $2.80. The average price target represents a 252.00% upside from the last price of $2.50.

This chart shows the closing price for IFRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 7 contributing investment analysts is to hold stock in InflaRx. This rating has held steady since June 2021, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 2 sell ratings
2/12/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 2 sell ratings
5/12/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/10/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
11/8/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
2/6/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 0 sell ratings
5/7/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 1 sell ratings
7/6/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 1 sell ratings
8/5/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/19/2021SVB LeerinkReiterated RatingBuy$6.00Low
5/13/2021Credit Suisse GroupLower Price TargetUnderperform$3.50 ➝ $2.80High
5/13/2021Raymond JamesLower Price TargetOutperform$12.00 ➝ $11.00High
3/26/2021HC WainwrightLower Price TargetBuy$12.00 ➝ $10.00Low
3/11/2021GuggenheimUpgradeNeutral ➝ Buy$16.00High
1/13/2021HC WainwrightReiterated RatingBuyMedium
1/7/2021HC WainwrightBoost Price TargetBuy$11.00 ➝ $12.00N/A
11/6/2020SVB LeerinkUpgradeMarket Perform ➝ Outperform$7.00 ➝ $10.00Low
10/30/2020Lifesci CapitalReiterated RatingMarket PerformLow
10/8/2020HC WainwrightInitiated CoverageBuy$11.00Medium
9/14/2020Ci CapitalReiterated RatingHold$7.00High
7/31/2020Raymond JamesLower Price TargetOutperform$20.00 ➝ $19.00High
6/17/2020Raymond JamesReiterated RatingBuyMedium
6/16/2020BTIG ResearchInitiated CoverageBuy$12.00High
5/28/2020Ci CapitalReiterated RatingHold$7.00Medium
5/21/2020BMO Capital MarketsBoost Price TargetMarket Perform$4.00 ➝ $7.00Medium
5/21/2020Raymond JamesBoost Price TargetOutperform$10.00 ➝ $20.00High
5/7/2020SVB LeerinkBoost Price TargetHold$4.00 ➝ $7.00Low
4/29/2020Raymond JamesUpgradeMarket Perform ➝ Outperform$10.00High
7/19/2019Raymond JamesReiterated RatingHoldN/A
6/5/2019SVB LeerinkDowngradeOutperform ➝ Market PerformLow
6/5/2019Raymond JamesDowngradeOutperform ➝ Market PerformHigh
6/5/2019Credit Suisse GroupDowngradeOutperform ➝ UnderperformHigh
6/5/2019BMO Capital MarketsDowngradeOutperform ➝ Market Perform$5.00High
6/5/2019SunTrust BanksDowngradeBuy ➝ Hold$55.00 ➝ $5.00High
6/5/2019Robert W. BairdDowngradeOutperform ➝ Neutral$58.00 ➝ $6.00High
6/5/2019JPMorgan Chase & Co.DowngradeOverweight ➝ Underweight$67.00 ➝ $9.00High
6/5/2019GuggenheimDowngradeBuy ➝ Neutral$65.00 ➝ $6.00High
5/24/2019Raymond JamesSet Price TargetBuy$44.00Medium
4/24/2019BMO Capital MarketsBoost Price TargetOutperform$64.00High
3/29/2019Robert W. BairdLower Price TargetOutperform ➝ Outperform$62.00 ➝ $58.00High
2/22/2019GuggenheimInitiated CoverageBuy$65.00Low
2/5/2019JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Top Pick$42.00 ➝ $65.00High
1/28/2019Robert W. BairdInitiated CoverageOutperform$62.00High
12/10/2018Credit Suisse GroupInitiated CoverageOutperform ➝ Outperform$47.00Low
7/13/2018BMO Capital MarketsInitiated CoverageOutperform$45.00Medium
6/28/2018Raymond JamesInitiated CoverageOutperform$44.00High
6/28/2018SunTrust BanksInitiated CoverageBuy$55.00High
5/18/2018SVB LeerinkReiterated RatingOutperform$42.00Low
4/2/2018SVB LeerinkBoost Price TargetOutperform$31.00 ➝ $36.00Low
2/8/2018B. RileyInitiated CoverageBuy ➝ Buy$40.00Low
12/4/2017BMO Capital MarketsInitiated CoverageOutperform$31.00High
12/4/2017SVB LeerinkInitiated CoverageOutperform$31.00High
12/4/2017JPMorgan Chase & Co.Initiated CoverageOverweight$30.00High
(Data available from 8/5/2016 forward)
InflaRx logo
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in the Germany and United States. Its C5a is an inflammatory mediator that is involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, an intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of pyoderma gangrenosum, a chronic inflammatory skin disorder, as well as developing IFX-1 for the treatment of oncological diseases. It also develops IFX-2 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. InflaRx N.V. has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.
Read More

Today's Range

Now: $2.50
Low: $2.45
High: $2.56

50 Day Range

MA: $2.89
Low: $2.48
High: $3.21

52 Week Range

Now: $2.50
Low: $2.36
High: $6.88

Volume

48,291 shs

Average Volume

127,819 shs

Market Capitalization

$108.08 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.46

Frequently Asked Questions

What sell-side analysts currently cover shares of InflaRx?

The following sell-side analysts have issued research reports on InflaRx in the last year: Ci Capital, Credit Suisse Group AG, Guggenheim, HC Wainwright, Lifesci Capital, Raymond James, SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for IFRX.

What is the current price target for InflaRx?

6 Wall Street analysts have set twelve-month price targets for InflaRx in the last year. Their average twelve-month price target is $8.80, suggesting a possible upside of 252.0%. Guggenheim has the highest price target set, predicting IFRX will reach $16.00 in the next twelve months. Credit Suisse Group AG has the lowest price target set, forecasting a price of $2.80 for InflaRx in the next year.
View the latest price targets for IFRX.

What is the current consensus analyst rating for InflaRx?

InflaRx currently has 1 sell rating, 2 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in IFRX, but not buy more shares or sell existing shares.
View the latest ratings for IFRX.

What other companies compete with InflaRx?

How do I contact InflaRx's investor relations team?

InflaRx's physical mailing address is WINZERLAER STR. 2, JENA 2M, 07745. The company's listed phone number is 49-36-4150-8180 and its investor relations email address is [email protected] The official website for InflaRx is www.inflarx.de.